- Home
- COCP vs NERV Comparison
COCP vs NERV Comparison
Compare COCP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COCP | NERV |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 29.2M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | COCP | NERV |
|---|---|---|
| Price | $0.98 | $4.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 53.5K | 41.8K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $1.15 |
| 52 Week High | $3.26 | $12.46 |
Technical Indicators
Market Signals| Indicator | COCP | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 55.96 |
| Support Level | $0.95 | $3.70 |
| Resistance Level | $1.05 | $4.07 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 19.66 | 90.59 |
Price Performance
Historical ComparisonAbout COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.